Pharmacy World & Science

, Volume 29, Issue 4, pp 412–421 | Cite as

Pharmacy care perspectives on problems with HIV antiretroviral therapy in Sweden

  • Amadou JallowEmail author
  • Sofia Kälvemark-Sporrong
  • Lilian Walther-Jallow
  • Peter M. Persson
  • Urban Hellgren
  • Örjan Ericsson
Original Paper



This study has three main objectives (1) to identify the major problems or difficulties pharmacy staff in Sweden experience regarding pharmacy care of patients receiving antiretroviral therapy, (2) to identify the perceptions of pharmacy staff regarding what are patient-related concerns with antiretroviral therapy and (3) to compare the extent to which pharmacy staff awareness matches patient perceptions regarding what are the major problems or difficulties associated with antiretroviral therapy.


A problem detection study (PDS) containing two questionnaires was conducted: one to be completed by pharmacy staff and another to be completed by both pharmacy staff and patients. In the latter survey, staff were asked about what they thought that patients would have responded. Staff and patient responses were then matched and compared with one another.


The pharmacy staff expressed their need for continuous education so as to assist the patients with their complex regimens. The staff were aware that patients were worried about therapy failure and viral resistance, medication-related problems and negative attitudes from the public. The staff however were less aware of the extent to which patients worried about not having their HIV infection under control. The staff also valued written patient information to a much higher extent than the patients.


The pharmacy staff’ awareness of the major problems HIV patients are experiencing seems incomplete and may lead to lack of concordance between the patients and pharmacy staff. This in turn may lead to non-adherence and poor therapy outcomes. Pharmacy staff should be encouraged to improve and systematically assess patient issues regarding antiretroviral therapy. Through assessing patient needs and concerns, the pharmacists can better identify patient needs and thus better tailor their educational and behavioural interventions to improve therapy outcomes.


Adherence AIDS Antiretroviral therapy Concordance Drug-related problems Drug-use problems HIV Patient counselling Pharmacy care Pharmacy staff Sweden 



Funding This work was funded by the National Corporation of Swedish Pharmacies (Apoteket AB) and the Swedish Foundation for Strategic Research. The authors thank Sveriges Farmaceutiska Sällskap for awarding a scholarship to the project and pharmacist Lena Lagerholm for assistance. Special thanks to the staff of RFHP (the Swedish Group for HIV Positives), Convictus (former injecting drug users) and OASEN (group for origins of Sub-Saharan Africa) for their invaluable support in collecting the study data. We are most grateful to the staff at the Stockholm pharmacies (Huddinge University Hospital, Ugglan, South Hospital, C W Scheele, Enhörningen, Karolinska, and Danderyd) and Clinics (Huddinge University Hospital, Danderyd Hospital, South Hospital, and Karolinska Hospital). Thanks to the Pharmacist Mr and Mrs Mgbemena for reading the final stage of the manuscript.


  1. 1.
    Hogg RS, Heath KV, Yip B, Craib KJ, O’Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450–4PubMedCrossRefGoogle Scholar
  2. 2.
    Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853–60PubMedCrossRefGoogle Scholar
  3. 3.
    Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d’Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22–9PubMedCrossRefGoogle Scholar
  4. 4.
    Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society—USA panel. JAMA 1997; 277:1962–9PubMedCrossRefGoogle Scholar
  5. 5.
    Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998;279:1977–83PubMedCrossRefGoogle Scholar
  6. 6.
    Harrigan PR, Whaley M, Montaner JG. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999;13:F59–62PubMedCrossRefGoogle Scholar
  7. 7.
    Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21–30PubMedGoogle Scholar
  8. 8.
    Chesney M. Adherence to HIV medications. Clin Infect Dis 2000;30 (suppl 2):642–60Google Scholar
  9. 9.
    O’Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003;34:407–14PubMedCrossRefGoogle Scholar
  10. 10.
    Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13:2493–505PubMedCrossRefGoogle Scholar
  11. 11.
    Romano L, Venturi G, Giomi S, Pippi L, Valensin PE, Zazzi M. Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. J Med Virol 2002;66:143–50PubMedCrossRefGoogle Scholar
  12. 12.
    Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. AI424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003;32:18–29PubMedGoogle Scholar
  13. 13.
    Singh N, Berman SM, Swindells S, Justis JC, Mohr JA, Squier C, et al. Adherence of human immunodeficiency virusinfected patients to antiretroviral therapy. Clin Infect Dis 1999;29:824–30PubMedGoogle Scholar
  14. 14.
    Barlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr 2002;29(Suppl 1):S2–10Google Scholar
  15. 15.
    Schering Laboratories. Improving patient compliance: is there a pharmacist in the house? Schering Report XIV. Kenilworth, NJ: Schering Laboratories; 1992Google Scholar
  16. 16.
    Haddad M, Inch C, Glazier RH, Wilkins AL, Urbshott GB, Bayoumi A, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev 2000;(3):CD001442Google Scholar
  17. 17.
    Knobel H, Carmona A, Lopez JL, Gimeno JL, Saballs P, Gonzalez A, et al. Adherence to very active antiretroviral treatment: impact of individualized assessment. Enferm Infecc Microbiol Clin 1999;17:78–81PubMedGoogle Scholar
  18. 18.
    Simoni JM, Frick P, Pantalone D, Turner BJ. Antiretroviral adherence interventions: a review of current literature and ongoing studies. Topics HIV Med 2003;11:185–98Google Scholar
  19. 19.
    Kansanaho HM, Puumalainen II, Varunki MM, Airaksinen MS, Aslani P. Attitudes of Finnish community pharmacists toward concordance. Ann Pharmacother 2004;38(11):1946–53. [Epub 2004 Oct 5]Google Scholar
  20. 20.
    Cote I, Gregoire JP, Moisan J, Chabot I. Quality of life in hypertension: the SF-12 compared to the SF-36. Can J Clin Pharmacol. 2004 Fall;11(2):e232–8Google Scholar
  21. 21.
    Bajramovic J, Emmerton L, Tett SE. Perceptions around concordance—focus groups and semi-structured interviews conducted with consumers, pharmacists and general practitioners. Health Expect 2004;7(3):221–34PubMedCrossRefGoogle Scholar
  22. 22.
    Skoglund P, Isacson D, Kjellgren KI. Analgesic medication—communication at pharmacies. Patient Educ Couns 2003;51(2):155–61PubMedCrossRefGoogle Scholar
  23. 23.
    Rosenqvist U, Höglund A, Nilsson JLG. Diabetes mass education for patients. Drug Inform J 1995;29:609–16Google Scholar
  24. 24.
    Lisper B, Nilsson JL. The asthma year in Swedish pharmacies: a nationwide information and pharmaceutical care program for patients with asthma. Ann Pharmacother 1996;30:455–60PubMedGoogle Scholar
  25. 25.
    Wade AH, Weir DN, Cameron AP, Tett SE. Using a problem detection study (PDS) to identify and compare health care provider and consumer views of antihypertensive therapy. J Hum Hypertens (2003);17:397–405PubMedCrossRefGoogle Scholar
  26. 26.
    World Health Organization. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: WHO; 2003. Available at: Accessed August 24, 2004
  27. 27.
    Rabkin JG, Chesney MA. Treatment adherence to HIV medications. In: Kalichman SC, editor. Psychosocial and public health impact of new HIV therapies. New York: Kluwer Academic/Plenum Publishers; 1999. pp. 61–82Google Scholar
  28. 28.
    Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001;134:968–77PubMedGoogle Scholar
  29. 29.
    Knobel H, Guelar A, Carmona A, Espona M, Gonzalez A, Lopez-Colomes JL, et al. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care STDS 2001;15:193–9PubMedCrossRefGoogle Scholar
  30. 30.
    American Pharmacists Association. Medication compliance-adherence-persistence (CAP) digest. Washington, DC: APhA; 2003Google Scholar
  31. 31.
    Krueger KP, Felkey BG, Berger BA. Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. J Am Pharm Assoc 2003;43:668–79CrossRefGoogle Scholar
  32. 32.
    Hulka BS, Kupper LL, Cassel JC, Burdette JA. Communication, compliance, and concordance between physician and patients with their prescribed medications. Am J Public Health 1976;66:847–53PubMedCrossRefGoogle Scholar
  33. 33.
    Sbarbaro JA. The patient–physician relationship: compliance revisited. Ann Allergy 1990;64:325–31PubMedGoogle Scholar
  34. 34.
    Bertholon DR, Rossert H, Korsia S. The patient’s perspective on life with antiretroviral treatment: results of an 887-person survey. AIDS Reader 1999;9:462–9PubMedGoogle Scholar
  35. 35.
    Roberts KJ, Volberding P. Adherence communication: a qualitative analysis of physician–patient dialogue. AIDS 1999;13:1771–8PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Amadou Jallow
    • 1
    Email author
  • Sofia Kälvemark-Sporrong
    • 2
  • Lilian Walther-Jallow
    • 3
  • Peter M. Persson
    • 4
  • Urban Hellgren
    • 5
  • Örjan Ericsson
    • 6
  1. 1.Apoteket KällanNorsborgSweden
  2. 2.Apoteket ABStockholmSweden
  3. 3.Department of Medicine, Center for Infectious Medicine, Karolinska InstituteKarolinska University HospitalStockholmSweden
  4. 4.Hospital PharmacyKarolinska University HospitalStockholmSweden
  5. 5.Unit of Infectious DiseasesKarolinska University HospitalStockholmSweden
  6. 6.Department of Health and Medical ServicesThe National Board of Health and WelfareStockholmSweden

Personalised recommendations